Humacyte, Inc. (HUMAW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 350K 700K 1.1M Q3 '20: 914K Q3 '21: 241K Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 517K Q2 '25: 301K Q3 '25: 753K Q4 '25: 467K Q1 '26: 495K Q2 '26: 406K Q3 '21 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit Quarterly

-9M -6M -3M 0 3M 6M 9M Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 370K Q2 '25: 88K Q3 '25: 493K Q4 '25: -8.6M Q1 '26: -1.5M Q2 '26: -825K Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -20.5M Q4 '21: -21.6M Q1 '22: -21.8M Q2 '22: -18.5M Q3 '22: -23.5M Q4 '22: -20.8M Q1 '23: -22.5M Q2 '23: -26.7M Q3 '23: -24.6M Q4 '23: -26.2M Q1 '24: -26.6M Q2 '24: -29.5M Q3 '24: -30.2M Q4 '24: -28.1M Q1 '25: -23.2M Q2 '25: -29.7M Q3 '25: -24.4M Q4 '25: -30.8M Q1 '26: -28.9M Q2 '26: -27M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -31.6M Q4 '21: 42.6M Q1 '22: -19.8M Q2 '22: 36.9M Q3 '22: -25.3M Q4 '22: -3.7M Q1 '23: -37M Q2 '23: -22.7M Q3 '23: -26M Q4 '23: -25.1M Q1 '24: -31.9M Q2 '24: -56.7M Q3 '24: -39.2M Q4 '24: -20.9M Q1 '25: 39.1M Q2 '25: -37.7M Q3 '25: -17.5M Q4 '25: -24.8M Q1 '26: -17.6M Q2 '26: -36.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 3.5M 7M 10.5M Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 0 Q1 '25: 147K Q2 '25: 213K Q3 '25: 260K Q4 '25: 9.1M Q1 '26: 2M Q2 '26: 1.2M Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -30.5M Q4 '21: -21.4M Q1 '22: -18.8M Q2 '22: -16.6M Q3 '22: -16.8M Q4 '22: -19M Q1 '23: -18.6M Q2 '23: -22.6M Q3 '23: -13M Q4 '23: -19.1M Q1 '24: -27.3M Q2 '24: -21.3M Q3 '24: -22.9M Q4 '24: -26.6M Q1 '25: -28.6M Q2 '25: -26.4M Q3 '25: -23.9M Q4 '25: -26.1M Q1 '26: -25.1M Q2 '26: -22.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -30.6M Q4 '21: -21.5M Q1 '22: -18.8M Q2 '22: -16.7M Q3 '22: -17M Q4 '22: -19.6M Q1 '23: -19.8M Q2 '23: -23.1M Q3 '23: -13.5M Q4 '23: -19.2M Q1 '24: -27.7M Q2 '24: -21.5M Q3 '24: -23.8M Q4 '24: -26.6M Q1 '25: -28.8M Q2 '25: -27M Q3 '25: -24M Q4 '25: -26.2M Q1 '26: -25.3M Q2 '26: -22.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q3 '20: 5.8M Q1 '21: 5.9M Q2 '21: 5.9M Q3 '21: 44M Q1 '22: 103M Q2 '22: 103.9M Q3 '22: 103M Q1 '23: 103.3M Q2 '23: 103.4M Q3 '23: 103.4M Q1 '24: 108.2M Q2 '24: 119.2M Q3 '24: 119.4M Q1 '25: 131.8M Q2 '25: 155.4M Q3 '25: 158.3M Q1 '26: 197.8M Q2 '26: 234.2M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q3 '21: -9.87 Q4 '21: -0.66 Q1 '22: 2.61 Q2 '22: 5.85 Q3 '22: 6.32 Q4 '22: -0.12 Q1 '23: -0.29 Q2 '23: -0.86 Q3 '23: -0.86 Q4 '23: -1.07 Q1 '24: -1.00 Q2 '24: -1.26 Q3 '24: -1.34 Q4 '24: -1.26 Q1 '25: -0.69 Q2 '25: -0.45 Q3 '25: -0.23 Q4 '25: -0.26 Q1 '26: -0.63 Q2 '26: -0.55 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.